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Fragile X syndrome is themost common inherited form of intellectual disability. Here we report on a study based on a collaborative
registry, involving 12 Spanish centres, of molecular diagnostic tests in 1105 fragile X families comprising 5062 individuals, of whom,
1655 carried a full mutation or weremosaic, three cases had deletions, 1840 had a premutation, and 102 had intermediate alleles. Two
patients with the full mutation also hadKlinefelter syndrome.We have used this registry to assess the risk of expansion fromparents
to children. From mothers with premutation, the overall rate of allele expansion to full mutation is 52.5%, and we found that this
rate is higher for male than female offspring (63.6% versus 45.6%; 𝑃 < 0.001). Furthermore, in mothers with intermediate alleles
(45–54 repeats), there were 10 cases of expansion to a premutation allele, and for the smallest premutation alleles (55–59 repeats),
there was a 6.4% risk of expansion to a full mutation, with 56 repeats being the smallest allele that expanded to a full mutation allele
in a single meiosis. Hence, in our series the risk for alleles of <59 repeats is somewhat higher than in other published series. These
findings are important for genetic counselling.
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1. Introduction
Fragile X syndrome (FXS) is the most common cause of
inherited intellectual disability (ID) [1]. It is an X-linked
dominant disease with incomplete penetrance, affecting
approximately 1/3717 to 1/8918 Caucasianmales [2]. Although
rare, it is one of the most prevalent genetic disorders; this is
the reason for its medical and social importance.
In affected males, the syndrome is characterised by mod-
erate-to-severe mental retardation with behavioural distur-
bances such as hyperactivity and stereotypic hand flap-
ping in addition to variable dysmorphic features such as
large everted ears, elongated face, and postpubertal macro-
orchidism [1]. Affected females tend to have milder symp-
toms of FXS than males and they rarely show physical
features.
The FMR1 gene was identified in 1991, and FXS is now
known to be caused by the anomalous expansion of a trin-
ucleotide CGG repeat located in the 5󸀠 end of this gene
at the FRAXA locus in Xq27.3 [3]. The number of CGG
repeats in the population has been classified into four groups
depending on repeat size: normal (N), with 6 to 44 repeats;
intermediate (IA)—also called “grey alleles”—with between
45 and 54 CGG repeats; premutation (PM) with between 55
and 200 repeats; and the so-called full mutation (FM) with
over 200 repeats [4]. In the last group, a secondmechanism is
triggered, the hypermethylation of the adjacent CpG island,
resulting in a shutdown of transcription and therefore lack
of production of the FMRP protein, which is the underlying
cause of the syndrome [5].
The term “premutation” was coined to reflect the fact that
PM carriers do not generally have ID but that their alleles
are usually unstable, resulting in an expansion of the CGG
repeats when transmitted by a female and, hence, offsprings
of female PM carriers are at risk of having FXS [3].The FMR1
PM affects both males and females and it seems that as many
as 1/130–260 females and 1/250–810males are carriers of a PM
[6]. In recent years, it has been seen that IAs may or may not
be unstable [7]. It has also been demonstrated that the risk
of expansion is related to the number of CGG repeats, with
smaller alleles being less likely to expand to a full mutation
than larger ones [5, 8].The smallest premutation that has been
reported to expand to a full mutation allele in one generation
had 59 CGG repeats [7].
It was initially thought that females with a PM were
completely asymptomatic, but it was soon realized that this
is not the case: in 1996, a family was described in which the
women with a PM presented with clinical symptoms seem-
ingly unrelated to ID: a premature ovarian failure leading to
premature menopause [9]. Over the years these findings have
been confirmed in numerous studies, all pointing to fragile
X-associated primary ovarian insufficiency (FXPOI), as a
phenotypic characteristic of PM carriers although only about
13–26% of them present with this trait [10]. Interestingly, full
mutation carriers do not seem to present FXPOI. Further-
more, PM alleles are associated with a significant elevation of
FMR1mRNA levels [11, 12] and it has been shown that carriers
of the FMR1 premutation are at risk of developing fragile
X-associated tremor/ataxia syndrome (FXTAS), a late-onset
neurodegenerative disorder usually affecting males over 50
years of age [13]. In short, fragile X (FX) is now understood
to be a family of disorders including FXS, FXPOI, and FXTAS
[1].
In Spain, the frequency of the FM alleles has been esti-
mated to be approximately 1 in 2633 [14] and 1 in 2466 [15]
in two different studies in male newborns, and the disease
prevalence has been estimated to be 1 : 5000–1 : 6800 in males
[16]. However, the real number of individuals with FM or
PM remains unknown, not only in Spain, but also in other
countries. Furthermore, clinical features are neither specific
nor constant in carriers of the FM or the PM and, hence, the
exact frequencies of all of these types of clinical involvement
remain unknown in most of the populations studied.
With the overall aim of adding our knowledge to what
is already known about this syndrome, we created a Fragile
X Registry so that we could use it to improve diagnosis,
prevention, and genetic counselling in these families. Thanks
to the collaboration of 12 clinical laboratories with members
of GIRMOGEN (a Spanish Network for the study of intellec-
tual disabilities of genetic origin) that have received samples
from patients all over Spain, we have collected clinical and
molecular information from 19 years of diagnostic work on
a large number of members of FX families. In this work,
we present the first part of the statistical analysis of this
data to provide new information to guide clinical practice,
specifically concerning the clinical indications, molecular
results, and transmission of the expansions for the purposes
of genetic counselling. Despite the large series already pub-
lished [7, 8, 14, 15, 17–19], this work is one of the few including
individuals within FX families; this is the reason for the
importance of this report.
2. Materials and Methods
2.1. Patients. Data from FX patients and their direct relatives
were retrospectively collected from clinical laboratories at
12 diagnostic reference centres of several Spanish regions.
Table 1 lists these centres and numbers of cases and families
recruited. The total number of individuals studied includes
all index cases (ICs) plus all their relatives, including prenatal
cases. We considered an IC as the first individual in a family
seeking genetic testing, the result of which indicated that
he/she was a carrier of a FM (in general, probands with ID) or
PM (patients with normal intelligence) (Table 2). A custom-
designed program (see Section 2.3) perfectly identified the
cases recorded in more than one laboratory, so that they
could be taken into account to ascertain the exact number of
different ICs. Each new positive PM or FM case not related
to others was considered a new family meaning that the
number of ICs is the same as the number of families. In
total, we have registered 1105 ICs or families and a total of
5062 cases, ICs included, that is, a total of 3957 relatives. It is
important to note that we have only included direct relatives
at risk by pedigree, excluding all that were not directly related
(spouses/partners of individuals with PM or FM, etc.). Some
of these families have been included in previous studies [20,
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Table 1: Participating laboratories/centres and their total number of individuals registered.
Laboratories/centres Number of casesin each centre Shared cases
Number of IC or
families in each centre
Hospital Cl´ınic (Barcelona) 1.623 116 405
Hospital V. Arrixaca (Murcia) 1.001 9 104
Hospital Universitario Cruces (Basque Country and Navarra) 744 24 125
Hospital La Fe (Valencia) 608 33 108
Hospital Ramo´n y Cajal (Madrid) 403 1 133
C. Sanitaria Parc Taul´ı (Sabadell-Catalonia) 225 117 97
Hospital Virgen Macarena (Sevilla) 184 29 78
Hospital Son Espases (Illes Balears) 149 12 35
Hospitales Miguel Servet and Lozano Blesa (Zaragoza) 101 3 32
Hospital regional de Ma´laga (Ma´laga and Sevilla) 82 27 21
IBGM, Universidad de Valladolid (Castilla-Leo´n) 76 4 35
F. Jime´nez Dı´az (Madrid) 54 1 27
Total number of individuals studied 5062a 378 1105b
aThe total sum is 5250 cases, but subtracting the 188 shared cases yields a total of 5062 different cases.
bThe total sum of families is 1200 families, of which 95 were shared, giving a total of 1105 different families.
21]. The registry was completed with individuals who under-
went molecular genetic testing between 1991 and 2009 who
provided informed consent for diagnostic testing.
2.2. Molecular Analysis. Molecular analysis of the FMR1
CGG repeat region was performed in different laboratories
following the same method, with an initial screen using
PCR analysis of the CGG repeat to exclude males with
a normal repeat or females showing two normal alleles,
based on the protocol proposed by Fu et al. [22]. In recent
years, some of the participating laboratories have used PCR
amplification using fluorescent-labelled primers, analysing
the size of the amplified fragments on a sequencer ABI310
(Applied Biosystems, Foster City, CA) [14] or PCR amplifi-
cation followed by detection with nonradioactive methods
[23]. Finally, to confirm suspected PMs, mosaic alterations,
or FMs, all laboratories used analysis by Southern blot with
the StB12.3 probe in DNA double digested with EcoRI + EagI
[24].
2.3. Data Collection. We created a standardised registry
program called ProGGen (an application developed on Lotus
Notes) for which Excel files were sent to each collabo-
rating laboratory along with detailed instructions on how
to complete each file. The design was developed accord-
ing to criteria established by clinicians, geneticists, and
molecular geneticists, members of the GIRMOGEN network
and involved in the genetic diagnosis of FX. Clinical and
molecular information comprised the date of birth, year of
sampling and study, cellular origin of DNA, sex, number and
methylation status of CGG repeats, CGG repeats of the car-
rier mother/father, mental status, facial dysmorphic features,
presence of macroorchidism (in males), and diagnoses of
FXPOI or FXTAS. Once received, the completed files were
imported into the aforementioned program, which detects
and cleans duplicate cases and then carries out the data
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Figure 1: Distribution of cases studied by the year of diagnosis
(1991–2009).
extraction, processing, and the statistical analysiswith its own
software.
3. Results
In total, 1200 index cases or families were registered but 95
were shared by two or more laboratories, and hence there
were in fact 1105 different families. The total number of
individuals entered on the database was 5250, but subtracting
378 shared cases, the total number of different cases—ICs
included—was 5062 (Table 1). This yields a total of 3957
females and males tested for each registered IC; that is, the
average pedigree size was 3.58. In 268 families we were only
able to study. or record, the IC and, at the other extreme, the
largest family registered comprises 55 individuals, including
the IC.
Figure 1 shows the distribution of the number of diag-
noses per year.Themean number of ICs studied per year was
4 BioMed Research International
Table 2: Medical indication for referral.
Number of males Number of females Total number
Patients with ID
With family history of ID
GDD, ID, and autism (all ages) 97 8 105
Studies in ID institutions 22 0 22
With no family history of ID
Children with GDD and or autism 461 55 516
ID in young patients and adults 113 13 126
Patients with normal intelligence
With family history of ID
Relative of a patient with FXS diagnosed in another centre 30 112 142
Individual with history of ID with unknown aetiology in his/her family 2 16 18
With no family history of ID
POI and/or menopause 0 17 17
FXTAS 10 3 13
Unknown reason to be studied 106 40 146
Total 841 264 1105
Table 3: Distribution of the 769 ICs with ID, by the age of the diagnosis of FXS.
Age of diagnosis 0–9 10–19 20–29 30–39 40–49 50–59 60+ Age unknown Total
Number of males 333 125 43 26 7 5 4 150 693
Number of females 37 16 5 5 2 0 1 10 76
Total 370 141 48 31 9 5 5 160 769
54.89 and this figure appears to be stable over the years. A
peak is observed in the total of individuals studied in 1992
because many of the FX families diagnosed before 1991 by
cytogenetic analysis were restudied that year with molecular
techniques. There were other smaller peaks in 2004-2005
when families began to be referred for testing because of
FXTAS or FXPOI.
Table 2 lists the ICs as a function of the reasons for refer-
ral, separating those with ID, developmental problems,
and/or autism from those with normal intelligence. As can
be seen, 17 ICs were detected among women tested because
they had ovarian failure and 13 (10 males and 3 females)
were detected among patients with suspected FXTAS. The
average age of the IC at diagnosis was 15.8 years (mean
calculated with the 840 ICs in which the age at diagnosis was
known), being this mean so high due to individuals seeking
genetic testing with normal intelligence (Table 2). As for the
subgroup of patients with ID, Table 3 classifies them by the
age of diagnosis, in 10 year bands, showing that 60.75% of ICs
(370/609) were less than 10 years old at diagnosis.
Table 4 shows the results of all the molecular tests per-
formed in the 5062 cases (postnatal and prenatal). Of the
total, 969 were FM males and 541 were FM females; 145
were mosaic (96 males and 49 females); 351 were PM males
and 1487 PM females, with the remaining 102 cases having
IAs. In addition, we have found three deletions, two in
prenatal diagnosis (1 female and 1 male). Interestingly, three
FM patients also carried a chromosomal abnormality: two
males had Klinefelter syndrome and one female (previously
reported [25]) had a mosaic Turner syndrome. It is also
notable that two FM males were classified as normal from
the point of view of intelligence; that is, they were high-
functioning men. Finally, one male with a PM also carried
a mutation in the FBN1 gene, causing Marfan syndrome.
Among the 271 prenatal diagnoses (Table 5) performed in
carrier pregnancies (PM or FM), the mutated allele had been
passed to the foetus in 147 cases (147/271 = 54.24%) and the
normal allele in 124 (124/271 = 45.75%). The difference is
not significant and thus there was no evidence of segregation
distortion of the alleles. Similarly, we found an excess of
males carrying the chromosome with the FX mutation but
the difference was not significant (78/147 = 53.06% versus
68/147 = 46.25%), so there does not appear to be any sex
ratio distortion among FX offsprings.
With all these molecular data, we wanted to analyse the
instability of the CGG repeat alleles inside the families, and in
order not to bias the analysis, we excluded ICs. Table 6 shows
the risk of expansion for females: the results are expressed
as the total number of sons and daughters with FMs and
PMs in pedigrees, having a mother with PM or IA whose
number ofCGGrepeats is known.Thesematernal repeat sizes
are distributed from ten to ten repeats. In general, there is a
growing likelihood of unstable transmissions with increasing
repeat size but four points are important to emphasize in
interpreting this table: (1) although the great majority of the
alleles withmore than 110 repeats expanded to a fullmutation,
the expansion risk was only 100% in two repeat ranges (140–
149 and 160–169); (2) in all ranges, except in one, the risk
BioMed Research International 5
Table 4: Results of the 5,062 molecular diagnostic tests performed in the 1105 different families (ICs and prenatal cases included).
FM Mosaics PM IA Deletions Normal Total
Number of males 969 96 351 42 2 692 2152
Number of females 541 49 1487 60 1 757 2895
Total 1510 145 1839a 102 3 1458a 5057b
aThe sex was unknown in 1 premutation and in 9 normal cases. All were prenatal cases (see Table 5).
bIn 5 cases, the molecular status was not recorded in the database.
Table 5: Molecular results of the prenatal studies performed in pregnant women carriers of an FM or PM.
FM Mosaics PM Deletions Total fragile-X Normal-X Total
Number of males 61 1 15 1 78 64 142
Number of females 51 2 14 1 68 51 119
Total 112 3 30a 2 147a 124a 271a
aThe sex was unknown in 1 premutation and in 9 normal cases.
of allelic expansion to FM is higher for male than female
offspring (63.6% versus 45.6%; 𝑃 < 0.001); (3) in the IA
group, there were 10 cases of expansion to a PM allele; and
(4) in the range of the smallest PM alleles (55–59 repeats),
there was a 6.4% risk of expansion to a full mutation, with 56
repeats being the smallest allele that expanded to a FM.
Finally, Table 7 shows the instability in the paternal trans-
missions. It is interesting that there were more expansions
than regressions (99 versus 40; 𝑃 < 0.001) but for men with
more than 140 repeats all daughters showed regressions of the
paternal repeat size.
4. Discussion
In clinical practice, the established technique for FXdiagnosis
is testing for the CGG expansion in the FM1 gene, what
we call molecular genetic diagnosis. In line with this, in
Spain all patients with suspected FX are referred for diagnosis
to reference centres which use molecular techniques and
the results are recorded in local databases that have been
operating within these centres since the identification of the
FMR1 gene. In 2006, the 12 largest molecular laboratories
(Table 1) decided to bring together the information contained
in the individual databases creating a single national registry.
The present study summarizes the compilation of molecular
data of 5062 individuals from 1105 different FX families from
19 years of diagnostic work. Although FXS is one of the most
prevalent genetic disorders, few analyses have been published
on large series of individuals belonging to fragile X families,
and hence the importance of our report.
From the point of view of clinical practice, we first want
to take note of the reasons for referral that resulted in the
diagnosis of a new FX family (Table 2). As we can see, 190 ICs
(190/1105 = 17.2%) had normal intelligence and they were
referred because they had a family history of ID, or because
they had an ovarian failure or there was suspicion of FXTAS,
and all were found to be carriers of a PM. The diagnosis of
new FX families with these selection criteria confirms what
has been recommended by the FXAmerican ExpertWorking
Group [26] in the sense that all these reasons for referrals
are associated with a high rate of identification of affected
individuals and carriers.
Considering the distribution by the age at diagnosis of the
609 ICs with ID for which this age was recorded (Table 3), we
observe that only 370/609 (60.75%) were less than 10 years
old and as many as 98 ICs were adults (98/609 = 16%). These
data can be explained by the fact that in the early years,
most studies were performed in adults from institutions for
individuals with intellectual disabilities. Table 3 also shows
that the IC was a female in 10% of the detected FMs (76
out of 769 cases), a figure similar to others published [17].
Figure 1 shows the distribution of the patients according to
the year of diagnosis. Looking at the curve of the ICs, we
can see that the number of diagnoses per year has been
more or less stable with three small peaks: the first one in
1995, which corresponds to studies in institutions; the second
one in 2001, which may correspond to a more widespread
awareness of these tests among paediatricians; finally, a third
peak in 2004, when tests were introduced for FXPOI and
FXTAS. Overall, despite the fact that the number of tests
carried out in our centres has increased considerably in recent
years (data not shown), it seems that we have reached a ceiling
in the detection of new families per year with an incidence of
about 50 families. Returning to the cases of ID, we have found
no changes in the age at diagnosis of FXS during the last 10
years of records and hence our data indicate that, despite all
the information paediatricians and teachers have about FXS,
the identification of new cases at younger ages continues to
be a challenge [27].
In the event of a positive diagnosis (a new IC), an exten-
sion of the molecular study to relatives has always been
proposed in Spain, following standard recommendations [4,
17, 26, 28] on cascade testing in the extended family. In total,
3957 females and males were tested (3.58/IC), including 271
prenatal diagnoses (Tables 4 and 5). Table 4 shows that there
were more males identified with the full mutation and more
females with the premutation as has been reported previously
in families [5, 17, 20, 21] and this is attributable to the fact that
the great majority of males tested had intellectual disability
(Table 2), and their mothers were frequently carriers of
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Table 6: Mutation expansion risks for carrier females of a PM or IA (including PN cases but not ICs).
Maternal repeat
size
Male offspring Female offspring Total
Number of
premutation
Number of
full
mutation
% full
mutation
Number of
PM
Number
of. full
mutation
% full
mutation
Number of
PM
Number of
full
mutation
% full
mutation
44–49 0 0 0.0 0 0 0.0 0 0 0.0
50–54 4 0 0.0 6 0 0.0 10 0 0.0
55–59 11 0 0.0 33 3 8.3 44 3 6.4
60–69 22 7 24.1 60 11 15.5 82 18 18.0
70–79 26 24 48.0 53 30 36.1 79 54 40.6
80–89 18 31 63.3 36 30 45.5 54 61 53.0
90–99 2 21 91.3 12 28 70.0 14 49 77.8
100–109 2 22 91.7 5 22 81.5 7 44 86.3
110–119 1 7 87.5 0 15 100.0 1 22 95.7
120–129 0 10 100.0 2 7 77.8 2 17 89.5
130–139 0 13 100.0 1 12 92.3 1 25 96.2
140–149 0 3 100.0 0 5 100.0 0 8 100.0
150-159 0 3 100.0 1 2 66.7 1 5 83.3
160–169 0 5 100.0 0 7 100.0 0 12 100.0
170–199 1 6 85.7 0 3 100.0 1 9 90.0
Total 87 152a 63.6a 209 175a 45.6a 296 327 52.5
aDifferences in the risk of expansion from PM to FM between males and females offsprings has statistical significance (𝑃 < 0.001).
the premutation. Furthermore, there is an excess of total
females studied (2895 women versus 2152 males) indicating
the importance given to the knowledge of the carrier status
in females for reproductive purposes. In relation to mosaic
cases, although some other research in families [5] indicated
that male carriers with a full mutation have mosaic patterns
more frequently than females, our results do not corroborate
these data (96/1065 = 9% in males versus 49/590 = 8.3% in
females).
Regarding the finding of cases of Klinefelter and Turner
syndromes, it is interesting to recall that one of the advantages
of the FX test is the ability to detect some sex chromosome
abnormalities [8], in particular, with the observation either
in PCR or Southern blot analysis of two X chromosomes in
a male patient. In the large series published by Strom et al.
[8] and by Youings et al. [29] not a single case was found of
a male patient with both a sex chromosome aneuploidy and
a PM or FM allele. They reported a frequency of Klinefelter
syndrome of 1 : 702 [8] and 1 : 249 [29] among males studied
for FXS. In our registry, 2 of the 969 male patients with FM
also had Klinefelter syndrome; a rate intermediate between
those found in the aforementioned studies but in accordance
with the fact that Klinefelter Syndrome is, by far, the most
common sex chromosome aneuploidy. Since the FXS is the
most frequent genetic cause of ID, it should not be expected
to be rare for the two syndromes to cooccur in a patient.
In relation to prenatal diagnosis, in general, our results
corroborate those of previous large series [7, 18, 19] in the
sense that there was no evidence of segregation distortion of
the allele transmitted nor in the sex segregation. Although it
seems there is an excess of male foetuses compared to female
foetuses this difference was not statistically significant and
is consistent with other reports [8]. We underline that it is
important to bear the results in Table 5 in mind for genetic
counselling, because the overall cases recorded (Table 4)
correspond to a retrospective analysis of fragile X families
that may suffer from ascertainment bias, while prenatal data
are always considered prospective and not subject to this
source of error [19].
Concerning the mutation expansion risks for females
with IA or PM alleles (Table 6), our work also confirms
previous studies [7, 8, 18, 19] in the sense that the instability
of PM alleles increases with the size of alleles. It has been
suggested that the lower expansion rate of the smaller PMs
is due to the presence of an AGG sequence in the middle
of the CGG repeats that creates an anchor protecting against
expansion [7]. Since our molecular data were recorded with
the size alone, we have no way of knowing which cases
have AGG sequences. In any case, there are some differences
with the previous studies that we want to highlight. First, in
mothers with 50 to 54 repeats (IAs), they expanded to a PM
allele in 10 cases and in the range of the smallest PM alleles,
6.4% of alleles of 55 to 59 repeats expanded in a singlemeiosis
to a FM allele [30, 31]. Furthermore, for ICs (not included in
Table 6), the smallest maternal allele observed to expand to a
FM allele contained 56 repeats. Hence, in our series the risk
for alleles of <59 repeats is somewhat higher than in other
published series [8, 18, 19] and recommendations for prenatal
testing must be established in that range. Furthermore, in
our study, the alleles of up to 79 repeats expanded more
frequently to PM than to FM alleles and the highest rate of
full mutation expansion appeared in mothers with 90 repeats
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Table 7: Paternal transmissions to their daughters.
Paternal
repeat size
Number with the
same number of
repeats
Number
with
regression
Median of the
repeats average difference
%
regression
Number
with
expansion
Median of the
repeats average expansion
%
expansion
50–59 11 1 5.0 3.4 17 11.6 58.6
60–69 8 6 2.3 14.3 28 13.1 66.7
70–79 3 4 7.8 15.4 19 17.4 73.1
80–89 12 3 7.0 9.1 18 32.1 54.5
90–99 5 6 22.0 33.3 7 32.4 38.9
100–109 0 3 19.3 37.5 5 35.8 62.5
110–119 1 3 15.3 37.5 4 26.8 50.0
120–129 1 3 39.0 60.0 1 17.0 20.0
130–139 1 0 0 0.0 0 0 0.0
140–149 0 3 26.7 100.0 0 0 0.0
150-159 0 0 0 0.0 0 0 0.0
160–169 0 0 0 0.0 0 0 0.0
170–179 0 0 0 0.0 0 0 0.0
180–198 0 4 73.5 100.0 0 0 0.0
190–199 0 0 0 0.0 0 0 0.0
>200 0 4a 471.0 100.0 0 0 00.0
Total 42 40 22.1 99 54.7
aThese 4 daughters had PMs, with their fathers being 2 high functioning males.
ormore, whereasNolin et al. [19] observed this higher rate for
mothers with 80 repeats ormore.We also observed that, in all
ranges except one (110–119 repeats), the risk of expansion to
a FM is higher for male than female offspring (63.6% versus
45.6%; 𝑃 < 0.001), and that provides strong evidence that the
transition from PM to FM is a postzygotic event; that is,
it occurs after fertilization of the carrier oocyte [5]. These
patterns are of vital importance for genetic counselling.
Evidence from other triplet-repeat disorders also points
to postzygotic events that contribute to these differences
in the repeat instability. They have also been observed
in maternal transmissions of CAG repeats in Huntington
disease, with a tendency for expansion in male offspring and
contractions in female offspring [32]. In myotonic dystrophy
although contractions of the CTG repeats are much less
frequent than expansions, they are more frequently trans-
mitted by males [33]. In our study, contractions also occur
in maternal transmissions but only in a 2.6% of them, with
no differences between male and female offsprings. By the
contrary, it is interesting that, for carrier men, there were
more transmissions with expansions than contractions (99
versus 40;𝑃 < 0.001) but, formenwithmore than 140 repeats,
all daughters showed regressions in size—including four
daughters with a PM whose fathers had >200 repeats—
indicating oncemore that expansions are a postzygotic event.
Thus, events occurring after fertilisation may play a role in
determining repeat size in FX as it does in other expansion
disorders [32], and these events may be heritable as we
suggested in a previous work the possible existence of an
intrafamilial effect [12].
5. Conclusions
In conclusion, our data fully validate the use of molecular
genetic tests for fragile X in clinical practice. It also supports
and completes previous studies, adding more evidence and
additional data that may be useful for the purposes of genetic
and reproductive counselling.
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